Claims
- 1. A compound of the following formula: or its pharmaceutically acceptable salt, whereinR1 and R2, taken together with the carbon atom to which they are attached, form a mono-, bi-, or tri-cyclic group having 3 to 13 carbon atoms, wherein the cyclic group is optionally substituted by one to five substituents independently selected from halo, (C1-C4)alkyl, (C2-C4)alkenyl, (C1-C4)alkoxy, hydroxy, oxo, ═CH2 and ═CH—(C1-C4)alkyl, provided that the bi- or tri-cyclic group is not a benzo-fused ring; A is (C2-C5)alkenyl, (C2-C5)alkynyl, phenyl-(C1-C5)alkyl, phenyl or heteroaryl selected from furyl, thienyl, pyrrolyl and pyridyl, wherein the phenyl and heteroaryl are optionally substituted by one to three substituents selected from halo, (C1-C3)alkyl and (C1-C3)alkoxy; R is hydrogen, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C7)cycloalkyl, (C1-C6)alkanoyl, ((C1-C4)alkyl)-Z—(C1-C6)alkynyl, ((C3-C7)cycloalkyl)-Z—(C1-C6)alkyl, heterocyclic-(C1-C6)alkyl, phenyl-(C1-C6)alkyl, heterocyclic-(C1-C6)alkyl-Z—(C1-C6)alkyl, phenyl-(C1-C6)alkyl-Z—(C1-C6)alkyl, heterocyclic- Z—(C1-C6)alkyl, ((C3-C7)cycloalkyl)-heterocyclic-(C1-C6)alkyl, heterocyclic-heterocyclic- Z—(C1-C6)alkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl and heterocyclic are optionally substituted by one to three substituents selected from halo, hydroxy, amino, guanizino, carboxy, amidino, ureido, (C1-C3)alkyl, (C1-C3)alkoxy, and mono- or di-(C1-C4)alkylamino, and wherein Z is O, S, SO, SO2, CO, C(═O)O, OC(═O), N(R), C(═O)N(R) or N(R)CO; and X is phenyl, heterocyclic, (C1-C6)alkyl, (C2-C6)alkenyl, (C3-C7)cycloalkyl, (C2-C7)alkynyl, wherein the phenyl, heterocyclic, alkyl, alkenyl, cycloalkyl and alkynyl are optionally substituted by one to three substituents selected from halo, (C1-C3)alkyl and (C1-C3)alkoxy.
- 2. A compound according to claim 1, whereinR1 and R2, taken together with the carbon atom to which they are attached, form a monocyclic group selected from (C3-C13)cycloalkyl and (C3-C13)cycloalkenyl, wherein the monocyclic group is optionally substituted by one or two substituents independently selected from halo and (C1-C4)alkyl; A is phenyl-(C1-C5)alkyl or phenyl optionally substituted by one to three substituents independently selected from halo, (C1-C3)alkyl and (C1-C3)alkoxy, R is hydrogen, (C1-C6)alkyl, (C2-C6)alkenyl, heterocyclic-(C1-C6)alkyl or ((C1-C4)alkyl)-Z—(C1-C6)alkyl, wherein the alkyl, alkenyl and heterocyclic are optionally substituted by one to three substituents selected from halo, hydroxy, amino, guanizino, carboxy, amidino, ureido, (C1-C3)alkyl, (C1-C3)alkoxy, mono- and di-(C1-C4)alkylamino; and X is phenyl, heterocyclic, (C1-C6)alkyl or (C2-C6)alkenyl, wherein the phenyl, heterocyclic, alkyl and alkenyl are optionally substituted by one to three substituents selected from halo, (C1-C3)alkyl and (C1-C3)alkoxy.
- 3. A compound according to claim 2, wherein R1 and R2, taken together with the carbon atom to which they are attached, form a monocyclic group selected from (C5-C10)cycloalkyl and (C5-C10)cycloalkenyl, wherein the monocyclic group is optionally substituted by one or two substituents independently selected from (C1-C3)alkyl; A is phenyl or benzyl; R is hydrogen, (C1-C3)alkyl, amino-(C1-C6)alkyl, heterocyclic-(C1-C3)alkyl wherein the heterocyclic is optionally substituted by amino or ((C1-C4)alkyl)-Z—(C1-C6)alkyl wherein Z is OC(=O); and X is (C1-C3)alkyl or phenyl.
- 4. A compound according to claim 3, wherein R1 and R2, taken together with the carbon atom to which they are attached, form cyclohexyl, cycloheptyl or cycloheptenyl; A is phenyl or benzyl; R is hydrogen, aminopropyl, aminohexyl, piperidinylethyl, 4-aminopiperidinylethyl or methoxy-carbonylmethyl; and X is phenyl.
- 5. A compound selected from3-(3-aminopropyl)-1-phenyl-8-(1-phenylcycloheptyl)-1,3,8-triazaspirol[4.5]decan-4-one; and 8-(1-methylcycloheptyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one; and its pharmaceutically acceptable salts.
- 6. A pharmaceutical composition for the treatment of a disorder or condition in a mammal, wherein the disorder or condition is selected from the group consisting of inflammatory diseases, inflammation-related hyperalgesia, and pain, comprising an amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof that is effective in treating such disorder or conditions and a pharmaceutically acceptable carrier.
- 7. A method of treating a disorder or condition in a mammal, where the disorder or condition is selected from the group consisting of inflammatory diseases, inflammation-related hyperalgesia, and pain, comprising administering to said mammal an effective amount of the compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
Parent Case Info
This is a continuation of PCT/IB98/01702 filed Oct. 23, 1998.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
6043366 |
Adam et al. |
Mar 2000 |
A |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/IB98/01702 |
Oct 1998 |
US |
Child |
09/426824 |
|
US |